查看文章

PURPOSE

CheckMate 032 is an open-label, multicohort study that includes patients with unresectable locally advanced or metastatic urothelial carcinoma (mUC) treated with nivolumab 3 mg/kg monotherapy every 2 weeks (NIVO3), nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks (NIVO3+ IPI1), or nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks (NIVO1+ IPI3). We report on the expanded NIVO1+ IPI3 cohort and extended follow-up for the NIVO3 and NIVO3+ IPI1 cohorts.

METHODS

Patients with platinum-pretreated mUC were enrolled in this phase I/II multicenter study to receive NIVO3, NIVO3+ IPI1, or NIVO1+ IPI3 until disease progression or unacceptable toxicity. Primary end point was investigator-assessed objective response rate per …